--- title: "Gil Blum Maintains Hold Rating Amid Uncertainty on FT819 Durability and Rising Competition in Lupus Nephritis Cell Therapies" type: "News" locale: "en" url: "https://longbridge.com/en/news/286304011.md" description: "Needham analyst Gil Blum has maintained a Hold rating on FATE stock due to uncertainties surrounding the FT819 program in lupus nephritis. The RECLAIM-LN trial will assess FT819's efficacy in patients who have not responded to previous treatments. While FT819 shows potential, concerns about the durability of its benefits and rising competition from other therapies lead Blum to recommend a cautious approach until more data is available." datetime: "2026-05-13T18:45:51.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286304011.md) - [en](https://longbridge.com/en/news/286304011.md) - [zh-HK](https://longbridge.com/zh-HK/news/286304011.md) --- # Gil Blum Maintains Hold Rating Amid Uncertainty on FT819 Durability and Rising Competition in Lupus Nephritis Cell Therapies Needham analyst Gil Blum has maintained their neutral stance on FATE stock, giving a Hold rating today. ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Gil Blum has given his Hold rating due to a combination of factors, including the design and current data of the FT819 program in lupus nephritis. The registrational RECLAIM-LN trial will test a single FT819 dose after bendamustine lymphodepletion in roughly 53 patients who have failed at least two prior systemic treatments, with complete renal response at six months as the main efficacy measure. Although FT819 has demonstrated encouraging signals of activity, questions remain around the durability of benefit, particularly in light of incomplete B-cell depletion. In addition, systemic lupus erythematosus and lupus nephritis are becoming increasingly competitive, with other cell therapies such as rap-cel and obe-cel already in pivotal development, so Blum believes more follow-up and detailed data are needed before taking a more constructive stance on the stock, supporting his decision to keep a Hold recommendation. ### Related Stocks - [FATE.US](https://longbridge.com/en/quote/FATE.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) ## Related News & Research - [REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval](https://longbridge.com/en/news/286443456.md) - [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md) - [](https://longbridge.com/en/news/286807703.md) - [Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT](https://longbridge.com/en/news/286414681.md) - [Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push](https://longbridge.com/en/news/286623100.md)